Trial · NCT04793399
Adverse events17
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 17 of 17
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Bosutinib-Atezolizumab Combination | 7 | 9 | 10 |
| other | Vomiting | Gastrointestinal disorders | Bosutinib-Atezolizumab Combination | 3 | 9 | 5 |
| other | Nausea | Gastrointestinal disorders | Bosutinib-Atezolizumab Combination | 4 | 9 | 4 |
| other | Abdominal discomfort | Musculoskeletal and connective tissue disorders | Bosutinib-Atezolizumab Combination | 1 | 9 | 1 |
| other | Abdominal pain | Musculoskeletal and connective tissue disorders | Bosutinib-Atezolizumab Combination | 1 | 9 | 1 |
| other | Abdominal pain upper | Musculoskeletal and connective tissue disorders | Bosutinib-Atezolizumab Combination | 1 | 9 | 1 |
| other | Blood bilirubin increased | Hepatobiliary disorders | Bosutinib-Atezolizumab Combination | 1 | 9 | 1 |
| other | Headache | Nervous system disorders | Bosutinib-Atezolizumab Combination | 1 | 9 | 1 |
| other | Rash | Skin and subcutaneous tissue disorders | Bosutinib-Atezolizumab Combination | 1 | 9 | 1 |
| other | Pyrexia | General disorders | Bosutinib-Atezolizumab Combination | 1 | 9 | 1 |
| other | Lipase increased | Metabolism and nutrition disorders | Bosutinib-Atezolizumab Combination | 1 | 9 | 1 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Bosutinib-Atezolizumab Combination | 1 | 9 | 1 |
| other | Alanine aminotransferase increased | Hepatobiliary disorders | Bosutinib-Atezolizumab Combination | 1 | 9 | 2 |
| other | Aspartate aminotransferase increased | Hepatobiliary disorders | Bosutinib-Atezolizumab Combination | 1 | 9 | 1 |
| serious | Hepatotoxicity | Hepatobiliary disorders | Bosutinib-Atezolizumab Combination | 2 | 9 | |
| serious | Cholestasis | Hepatobiliary disorders | Bosutinib-Atezolizumab Combination | 1 | 9 | |
| serious | Transaminases Elevation | Hepatobiliary disorders | Bosutinib-Atezolizumab Combination | 1 | 9 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04793399/events